Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...

Tariffs should not influence decisions at Indian drug companies, Cipla's top executive said on Friday, as the industry braces ...

We would like most of the manufacturing to be centric in locations where it is most economic. Looking at every country's ...

Shares of Cipla are set to be in focus on Friday after the company received final approval from the U.S. Food and Drug Administration for its New Drug Application (NDA) for Nilotinib capsules ...

New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have ...

Industry leaders warn that potential US tariffs on Indian pharmaceutical exports could increase drug costs for American ...

India, often dubbed the "pharmacy of the world", is among the top exporters to the U.S., especially for cheaper versions of ...

The Indian Pharmaceutical Alliance (IPA) has proposed reducing the import duty on pharma products from the US to zero.

Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...

Indian pharmaceutical industry leaders indicate that proposed US tariffs on pharmaceutical exports may lead to increased drug ...

MUMBAI/BENGALURU, Feb 28 (Reuters) - Tariffs should not influence decisions at Indian drug companies, Cipla's (CIPL.NS), opens new tab top executive said on Friday, as the industry braces for U.S ...